Surgical Oncology

• Letter to Prospective Patients and Families
• Authorization for Release
• Consent to Treat
• Health History
• IPHC Information for Patients and Families
• Dr. Loggie’s Biography
• New Patient Checklist
• Patient Demographic (English)
• Referring Physicians
• Hotel Information

The Peritoneal Neoplastic Disease program continues to attract patients from across the country. This novel clinical program is one of a few such dedicated programs in the world and was established by Dr. Brian Loggie, who has a national and international reputation for his expertise in this field. We have seen patients from 40 states and several countries here at CUMC in the Cancer Center. These patients come for consultation regarding medical and surgical treatment options for a variety of cancers metastatic to or arising from the peritoneal lining surfaces of the abdomen and pelvis. Many patients have uncommon or rare disease entities and are seeking our extensive experience. These diseases include malignant peritoneal mesothelioma, various tumors of the appendix, and pseudomyxoma peritonei. Patients can also present with more common underlying diseases such as colon cancer or ovarian cancer. Treatment options include major operative tumor removal, also termed cytoreductive surgery (CS), which is combined in many cases with intraperitoneal heated chemotherapy (IPHC). CS+ IPHC is done here at CUMC on a regular basis. It is known as “the mother of all surgeries” in some patient circles and this is a testament to the difficulty and complexity of such surgical treatments.

We are pleased to have Dr. Jason Foster join our surgical oncology team and expand our ability to offer these complex treatments. Treatment and research go hand in hand. We currently have an ongoing clinical trial using intraperitoneal heated chemotherapy perfusion with high dose carboplatin for eligible patients with primary and recurrent ovarian cancer and for patients with malignant peritoneal mesotheliomas.  We also are continuing with ongoing translational research projects in an effort to expand or improve treatment options for our patients. There are research projects on mucinous tumors (such as pseudomyxoma peritonei) and malignant peritoneal mesotheliomas. We have received important research support from patients who have been pleased with their clinical care and recognize the importance of integrating research into the clinic. A major emphasis is placed on quality of life issues in determining the best treatment options for patients by integrating psycho-oncology services into our clinical program.

Dr. Loggie and Creighton University have been mentioned in various on-line newsletters by patients such as Sonoma Medicine, a magazine for the Sonoma County Medical Association in California, and Nursing Spectrum out of Chicago, Illinois. Additionally, on-line blogs maintained by patients mention the excellent care received by the staff in Surgical Oncology at Creighton University Medical Center. Grateful patients have donated more than $600,000 to cancer research related to mesothelioma and/or pseudomyxoma peritonei. Several patients and families have had or are planning fund raising events to fund research of these rare diseases. We appreciate the confidence in our clinical care and our research programs.